Article
In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
Antiviral therapy - 1 Jan 2007
Qi Xiaoping, Xiong Shelly, Yang Huiling, Miller Michael, Delaney William E
Abstract excerpt
BACKGROUND: Adefovir dipivoxil is a nucleotide prodrug approved for the treatment of chronic hepatitis B. During clinical trials, ADV-associated mutations were observed in 0, 3, 11, 18 and 29% of patients after 48, 96, 144, 192 and 240 weeks of therapy, respectively. Hepatitis B virus (HBV) polymerase mutations associated with virological breakthrough to ADV include rtA181V and rtN236T, which occur alone or in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.